血小板由来成長因子受容体 β 核プロモーター核酸過敏要素のG四重複とiモチーフの重複の結果は,突然変異の予期せぬ効果を説明し,小分子による両方の構造の選択的標的化のための機会を提供し,遺伝子発現を抑制する
Robert V Brown1, Ting Wang2, Venkateshwar Reddy Chappeta1
1College of Pharmacy, University of Arizona , 1703 East Mabel Street, Tucson, Arizona 85721, United States.
Journal of the American Chemical Society
|May 5, 2017
まとめ
研究者らは,PDGFR-βプロモーターのG-四重複素とiモチーフを標的とした新しい化合物を特定し,PDGFR-βの活性を低下させることで,急性肺損傷のような疾患の治療の可能性を示した.
科学分野:
- 分子生物学
- 遺伝学
- 薬理学について
背景:
- 血小板由来成長因子受容体β (PDGFR-β) 経路は,様々な疾患の主要な標的である.
- PDGFR-βプロモーターにG-四重複形成核素過敏要素 (NHE) が以前に確認された.
- このNHEにおけるG四重複とiモチーフの構造的および生物学的な役割は,さらなる調査を必要とする.
研究 の 目的:
- PDGFR-β NHEにおけるG四重複とiモチーフの構造と生物学的役割を調査する.
- PDGFR-β経路を標的とする新しい分子戦略を開発する.
- PDGFR-βの発現と活性を調節する化合物を特定する.
主な方法:
- PDGFR-β NHEにおけるG四重複とiモチーフ形成の構造分析
- ルシフェラーゼレポータープラズミドを用いたサイト指向型変異研究
- これらの構造を標的とする小分子 (エリプチシンとベンゾチオフェン-2-カルボキシアミド) のスクリーニングと特徴付け.
- プロモーターの活性,遺伝子発現,細胞増殖,移動を評価するインビトロ検査.
- 急性肺損傷のマウスモデルでの臨床前評価
主要な成果:
- GGA配列を持つ3'-end G-クアドルプレックスは,PDGFR-βの主な抑制剤である.
- PDGFR-β NHEの点変異は,G-四重複とi-モチーフ形成の均衡に影響する.
- エリプチシンアナログのGSA1129は,3'-end G-quadruplexを選択的に標的にする.
- ベンゾチオフェン-2-カルボキサミドNSC309874はPDGFR-βiモチーフと相互作用する.
- GSA1129とNSC309874はPDGFR-βプロモーターの活性とトランスクリプトレベルを低下させる.
- GSA1129はPDGFR-βによる細胞増殖と移動を阻害し,急性肺炎を vivoで緩和する.
結論:
- この研究は,PDGFR-βの調節における3'-end G-quadruplexの重要な役割を明らかにしている.
- G四重体とiモチーフ構造の相互作用と突然変異の影響を理解することは,遺伝子発現制御に極めて重要です.
- GSA1129とNSC309874は,急性肺損傷を含むPDGFR-β関連の病変に対する有望な治療薬です.
関連する概念動画
GPCR Desensitization
8.4K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
G Protein-coupled Receptors
18.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
18.4K
Receptor Downregulation in MVBs
2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.9K
Cooperative Binding of Transcription Regulators
7.4K
Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome. Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form...
7.4K
Amplifying Signals via Enzymatic Cascade
18.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
18.7K


